Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01526356 · ClinicalTrials.gov registry record · Phase 2
Topical Rapamycin to Erase Angiofibromas in TSC
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 179
- Enrollment target
NCT01526356 is a Phase 2 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 179 participants.
The verdict
NCT01526356, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 179 participants
- Enrollment target
Study Summary
The study is a multi-center prospective, randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of a topically applied formulation of rapamycin to cutaneous angiofibromas in subjects with Tuberous Sclerosis Complex (TSC). Subjects will apply either the topical vehicle containing rapamycin or the topical vehicle alone nightly to their angiofibromas for six months. The primary goal of this study is to evaluate the efficacy of the topical medication for reduction of cutaneous angiofibromas in patients with TSC. The secondary goal of this study is to confirm the safety of the topical medication.
Interventions
- DRUG Placebo
- DRUG Rapamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2012-05 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01526356
The ClinicalTrials.gov registry entry for NCT01526356 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01526356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01526356 about?
NCT01526356 is a clinical study titled "Topical Rapamycin to Erase Angiofibromas in TSC". The study is a multi-center prospective, randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of a topically applied formulation of rapamycin to cutaneous angiofibromas in subjects with Tuberous Sclerosis Complex (TSC). Subjects will apply either the topical vehicle con...
What is the current status of trial NCT01526356?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 179 participants. The study started on 2012-05. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01526356?
The interventions under investigation include: Placebo (DRUG), Rapamycin (DRUG).
Who is sponsoring clinical trial NCT01526356?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.